Arvinas (ARVN) Cash & Equivalents Growth (1y) (2018 - 2026)
Powered by 
Analysis
Arvinas (ARVN) Cash & Equivalents Growth (1y) (2018 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.61 Bn | 131.76 Bn | 2.84 Bn | 23.56% |
| 2 | Regeneron Pharmaceuticals | 85.86 Bn | 77.86 Bn | 3.93 Bn | 23.05% |
| 3 | Argenx Se | 63.53 Bn | 58.35 Bn | 1.37 Bn | 71.81% |
| 4 | Moderna | 58.41 Bn | 53.27 Bn | 52.00 Mn | 34.71% |
| 5 | Revolution Medicines | 43.97 Bn | 43.97 Bn | - | - |
| 6 | BeOne Medicines | 40.08 Bn | 34.98 Bn | 1.53 Bn | 84.98% |
| 7 | Alnylam Pharmaceuticals | 35.52 Bn | 32.21 Bn | 992.69 Mn | 53.39% |
| 8 | Royalty Pharma | 28.52 Bn | 27.68 Bn | - | 28.50% |
| 9 | Insmed | 27.47 Bn | 26.31 Bn | 358.27 Mn | -57.58% |
| 10 | Arvinas | 605.56 Mn | 37.66 Mn | - | -17.93% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -17.93% |
| Mar 31, 2026 | 7.78% |
| Dec 31, 2025 | 42.19% |
| Sep 30, 2025 | 19.13% |
| Jun 30, 2025 | -25.78% |
| Mar 31, 2025 | -7.95% |
| Dec 31, 2024 | -67.76% |
| Sep 30, 2024 | -25.07% |
| Jun 30, 2024 | 70.86% |
| Mar 31, 2024 | -32.41% |
| Dec 31, 2023 | 283.39% |
| Sep 30, 2023 | -14.25% |
| Jun 30, 2023 | -2.79% |
| Mar 31, 2023 | 108.99% |
| Dec 31, 2022 | -24.93% |
| Sep 30, 2022 | -48.13% |
| Jun 30, 2022 | 91.27% |
| Mar 31, 2022 | -82.00% |
| Dec 31, 2021 | -81.59% |
| Sep 30, 2021 | 187.30% |